Beneath the Surface: Which hair loss treatments work?

From topical minoxidil to oral finasteride, dermatologists have several options for treating hair loss in men and women, with emerging therapies showing promise in some clinical trials.
In this Beneath the Surface video interview, Joel M. Gelfand, MD, MSCE, FAAD, the James J. Leyden Professor of Clinical Investigation and professor of dermatology and epidemiology at University of Pennsylvania’s Perelman School of Medicine and Healio Dermatology’s Chief Medical Editor, spoke with Maryanne Makredes Senna, MD, director of the Lahey Hair Loss Center of Excellence at Lahey Clinic, about the most

Biomarkers may replace need for biopsies to diagnose, evaluate some glomerular diseases

In this video from ASN Kidney Week, Mark Haas, MD, PhD, discusses the role of the biopsy in several glomerular diseases and the potential usage of biomarkers in place of protocol or repeat biopsies.
“What came out of this session is that for certain diseases, we do have these biomarkers, and we can avoid repeat biopsies in a lot of these patients,” said Haas, renal pathologist and professor of pathology and laboratory services at Cedars-Sinai Medical Center in Los Angeles.
However, additional research is needed to develop noninvasive biomarkers for immunoglobulin A nephropathy, Haas

Complement distribution linked to disease activity in IgA nephropathy

In this video from ASN Kidney Week, Mark Haas, MD, PhD, discusses the role of the complement pathway in the pathogenesis of immunoglobulin A nephropathy.
“It’s not just the amount of complement but how the complement is distributed in the glomerulus within the immune complexes and the co-localization of complement with IgA that’s really important in terms of being associated with disease activity,” said Haas, renal pathologist and professor of pathology and laboratory services at Cedars-Sinai Medical Center in Los Angeles.
Additionally, further research is needed to

Chef Andrew Zimmern dishes out Thanksgiving food safety advice

Despite having five burners, three ovens, a plancha and two additional induction burners at his disposal, Chef Andrew Zimmern still relies on a pen and paper to plan Thanksgiving dinner.
The celebrity chef, who hosts approximately 20 guests for the holiday each year, said the biggest mistake he sees home cooks make is not necessarily overcooking or undercooking their turkey. Rather, it is failing to account for the time, space and equipment required to prepare a large holiday meal.
“I actually find that the majority of problems really are in a completely different category,” Zimmern, an Emmy-

Blood tests could help triage TBI patients

ED physicians can use blood tests to help triage patients who present with traumatic brain injury to determine if they need a potential escalation in care, according to research published in The Journal of Neurosurgery.
While CT scans remain the most objective way to assess intracranial injury, blood tests that measure key plasma biomarkers offer another useful tool for acute care hospitals trying to navigate overcrowding and resource allocation, said Shawn R. Eagle, PhD, assistant professor of neurosurgery at the University of Pittsburgh School of Medicine.
The results of a blood test could

AI-enabled CT increases diagnostic certainty in suspected CAD

CHICAGO — In symptomatic patients with suspected coronary artery disease, a strategy guided by AI-enabled quantitative CT increased diagnostic certainty compared with usual care, according to the results of the PARAMOUNT trial.
The AI-based quantitative coronary CT analysis (AI-QCT, Cleerly) was also associated with reduction in LDL compared with usual care, according to the presentation at the American Heart Association Scientific Sessions.
The AI-QCT system “takes those [CT] scans and it does an AI-enabled analysis of the coronary arteries, and there are several facets to that,” Todd C.

How to deprescribe medications in bipolar I disorder care

Deprescribing, or safely reducing or stopping medications that a person may no longer need, is receiving increased attention, especially in psychiatry where polypharmacy is often used to manage complex conditions like bipolar I disorder.
As prescribers, we spend considerable time learning how to initiate medications, adjust treatment and manage adverse effects. However, we receive less training on when and how to safely reduce or discontinue medications when they are no longer needed or benefiting patients.
It’s not uncommon to look at a medication list, even ones you’ve contributed

Passion for thyroid cancer research drives Megan. R. Haymart, MD

PHILADELPHIA — Conducting research that directly impacts patients with thyroid cancer has always been a focus for Megan R. Haymart, MD.
The University of Michigan has been the professional home since 2009 for Haymart, who is professor of medicine and the Nancy Wigginton Endocrinology Research Professor of Thyroid Cancer. Haymart, who is also a Healio | Endocrine Today Editorial Board Member, said she was attracted to the institution because of its solid reputation for health services research.
“The work that we have done over the years, hopefully, will help improve the care of thyroid cancer

AAOS insights panel reveals increasing clinical, personal burdens

The American Academy of Orthopaedic Surgeons’ Member Insights Panel revealed orthopedic surgeons hope to manage increasing administrative, clinical and mental health burdens through emerging technologies, according to a press release.
“Orthopedic surgeons are looking for ways to help streamline efficiencies in their clinics and their operating rooms,” Alexander P. Sah, MD, the codirector of Institute for Joint Restoration and Research and director of the outpatient joint replacement program at Washington Health in Fremont, California, told Healio. “There are great hurdles that the membership

JADE trial: OLN324 has ‘encouraging’ safety, mechanism of action in wet AMD

VIENNA — In this video, David A. Eichenbaum, MD, FASRS, discusses results from the phase 1b JADE clinical trial, which compared OLN324 with faricimab in patients with wet age-related macular degeneration.
In the trial, presented at the Euretina congress, patients with treatment-naive wet AMD received low-dose or high-dose OLN324 (Ollin BioSciences) or Vabysmo (faricimab, Genentech).
When compared with faricimab, patients who received OLN324 “seemed to have a better flattening of their pigment epithelial detachment,” Eichenbaum, of Retina Vitreous Associates of Florida, said.
In